The company’s leading program is a differentiated PPAR gamma agonist (MIN-102) being developed for X-linked Adrenoleukodystrophy (X-ALD) that has the potential to treat both cerebral ALD (cALD) and adrenomyeloneuropathy (AMN), as well as other orphan CNS indications such as Friedreich’s Ataxia (FRDA).

MIN-102 has initiated a phase 2/3 clinical trial in adult AMN patients and a phase 2 clinical trial in FRDA. Both studies are fully recruited.